According to filings with the U.S. Securities and Exchange Commission, Linnaeus Therapeutics is raising $3,088,234.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Patrick Mooney played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Linnaeus Therapeutics
Linnaeus is a Penn Center for Innovation UPstart company that was founded in 2016 and is based upon discoveries from the Ridky lab at the University of Pennsylvania. We are developing our initial therapies that are supported by a foundation of clinical experience. Being female and having a history of pregnancy are associated with decreased incidence and improved stage specific survival for many cancers, including melanoma, pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colon carcinomas.

To learn more about Linnaeus Therapeutics, visit http://www.linnaeustx.com/

Contact:
Patrick Mooney, Chief Executive Officer
856-433-1500
https://www.linkedin.com/in/patrick-mooney-5336093/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.